Ramucirumab 100mg Injection

Ramucirumab 100mg Injection is a highly specialized, fully human monoclonal antibody (IgG1) designed to disrupt the blood supply to tumors, a strategy known as angiogenesis inhibition. Tumors cannot grow beyond a certain size without developing their own network of blood vessels to deliver oxygen and nutrients. Ramucirumab 100mg Injection specifically targets the Vascular Endothelial Growth Factor Receptor 2 (VEGFR2). By binding to this receptor with high affinity, the medication physically blocks the natural ligands (VEGF-A, VEGF-C, and VEGF-D) from attaching. This blockade prevents the activation of the signaling pathways that trigger endothelial cell proliferation and new blood vessel formation. Essentially, it starves the cancer cells by cutting off their lifeline, leading to tumor regression and inhibiting metastatic spread. Discover how this professional pharmaceutical intervention provides the ultimate clinical strategy for managing advanced gastric, lung, and colorectal cancers, offering a targeted biological option that works synergistically with standard chemotherapies.

The 100mg/10ml vial is the precise dosing unit used to calculate patient-specific dosages based on body weight (typically 8 mg/kg or 10 mg/kg). This vial size is often used in conjunction with larger 500mg vials to minimize waste during preparation. The medication is administered via intravenous infusion every 2 or 3 weeks, depending on the indication. Unlike small-molecule inhibitors, Ramucirumab’s targeted antibody design minimizes off-target toxicities while maximizing the suppression of tumor vascularization.

Indications / Uses of Ramucirumab 100mg Injection

Ramucirumab 100mg Injection is commonly prescribed for the specialized management of the following advanced malignancies:

• Gastric/GEJ Cancer: It is indicated as a single agent or in combination with paclitaxel for the treatment of patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma who have progressed on prior fluoropyrimidine- or platinum-containing chemotherapy.
• Non-Small Cell Lung Cancer (NSCLC): The medication is used in combination with docetaxel for the treatment of patients with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy.
• Colorectal Cancer: It is indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) for the treatment of patients with metastatic colorectal cancer who have progressed on regimens containing bevacizumab, oxaliplatin, and a fluoropyrimidine.
• Hepatocellular Carcinoma: Ramucirumab 100mg Injection is used as a single agent for the treatment of patients with hepatocellular carcinoma (liver cancer) who have an Alpha Fetoprotein (AFP) level of ≥400 ng/mL and have been previously treated with sorafenib.

Key Features

• Specific VEGFR2 Blockade: The primary feature of Ramucirumab 100mg Injection is its direct inhibition of the primary receptor responsible for tumor angiogenesis, distinguishing it from drugs that target the ligand (VEGF).
• Starvation Mechanism: By preventing the formation of new blood vessels, it effectively limits the tumor’s supply of oxygen and nutrients.
• Synergistic Efficacy: Clinical trials demonstrate that it significantly improves overall survival when added to chemotherapy backbones like paclitaxel or docetaxel.
• 100mg Precision Vial: The 100mg unit allows for accurate dose titration and waste reduction when tailoring infusions to specific patient weights.
• Fully Human Antibody: As a fully human IgG1 antibody, it has a lower risk of inducing immunogenic reactions compared to chimeric antibodies.

Storage for Ramucirumab 100mg Injection

To preserve the structural integrity and biological activity of the monoclonal antibody, Ramucirumab 100mg Injection must be stored under refrigeration, typically between 2°C and 8°C (36°F to 46°F). Do not freeze and do not shake the vial, as mechanical stress can denature the protein. The vial should be kept in its original carton to protect it from light until the time of use. Once diluted in normal saline for infusion, the solution should be used immediately or stored under refrigeration for no more than 24 hours. Store the medication in a secure, professional medical refrigerator strictly out of the reach of children.

Important Note on Ramucirumab 100mg Injection

The administration of Ramucirumab 100mg Injection is associated with specific vascular and healing risks. Hemorrhage (Bleeding) is a significant risk; severe, sometimes fatal bleeding events (including gastrointestinal hemorrhage) have occurred. It should not be administered to patients with serious bleeding risks.

Impaired Wound Healing: Because it blocks blood vessel growth, Ramucirumab can disrupt wound healing. It must be withheld for at least 28 days prior to elective surgery and should not be resumed for at least 2 weeks following major surgery until the wound is fully healed.

Hypertension (high blood pressure) is a common side effect; blood pressure should be monitored before each administration. Proteinuria (protein in the urine) may also occur; urine protein levels should be monitored. Infusion-Related Reactions are possible; premedication with an antihistamine (e.g., diphenhydramine) is recommended for patients with a history of reactions. Ramucirumab 100mg Injection can cause fetal harm (Pregnancy Category D); effective contraception is mandatory. By strictly following these professional guidelines and surgical hold protocols, healthcare providers can safely maximize the survival benefits of Ramucirumab 100mg Injection.